2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Metabolism, Microbiome, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Health Outcomes Research, Study Population, Human, Adult, Animal Model
PAPER

4941 Induced somatic asxl1 variants in germline gata2 deficiency differentially alter developmental hematopoiesis

Megan Liu, Serine Avagyan, MD, PhD2
1 University of California San Francisco, San Francisco, California, United States
2 University of California San Francisco, San Francisco, California, United States

ASXL1 is one of the most common somatic genetic alterations in germline GATA2 deficiency-related hematological malignancy. Similar to aging-associated clonal hematopoiesis, ASXL1 variants occur early in malignant transformation. However, the reason behind the high prevalence of ASXL1 variants or the mechanism by which they lead to pre-malignancy in germline GATA2 deficiency remain unknown. Given the critical role of GATA2 in developmental hematopoiesis, we aimed to test the effect of ASXL1 variants using a robust model of mosaic somatic mutagenesis in developing zebrafish. Specifically, we posited that asxl1 variants alter developmental trajectory of gata2-deficient hematopoietic stem and progenitor cells (HSPCs). To test this hypothesis, we used CRISPR-Cas9 mutagenesis to induce asxl1 variants in zebrafish embryos with germline gata2b deficiency, generating mosaic crispants with insertions or deletions (indels) in exon 12 in some, but not all, cells of the embryo. Next-generation sequencing of whole embryos demonstrated a mean asxl1 variant allele frequency of 49.7±21.6% (n=49, subset of embryos). These crispants underwent whole-mount in situ hybridization (WISH) to assess developmental hematopoietic lineages based on detection of cell-type-specific gene expression.  Compared to control guide RNA-injected embryos, wildtype asxl1-crispant embryos had decreased itga2b-expressing HSPCs at 3 days post-fertilization (dpf) in the caudal hematopoietic tissue (CHT), the fetal HSPC niche (p < 0.001). At baseline, gata2bHET embryos also had reduced HSPCs compared to wildtype embryos, supporting the critical role of gata2b in HSPC development, conserved from zebrafish to humans. In contrast, gata2bHET asxl1-crispant embryos showed no changes in itga2b+ HSPCs compared to gata2bHET control embryos, suggesting that gata2b and asxl1 could interact to regulate HSPCs. Myeloid-primed c-myb-expressing progenitors in the CHT at 3 dpf decreased in both wildtype (p < 0.01) and gata2bHET (p < 0.05) asxl1-crispant embryos. No difference was observed in gata1a-expressing erythroid progenitors in the CHT at 3 dpf with asxl1 somatic mutagenesis in either germline background, suggesting that neither gata2b loss nor asxl1 variants affect primitive or early definitive erythropoiesis during early development. In the lymphopoietic lineage, rag1 expression in the thymus at 5 dpf decreased in wildtype asxl1-crispant embryos, but this effect was abrogated in gata2bHET asxl1-crispants, although no difference was observed in baseline rag1-expressing thymic progenitors in control wildtype and gata2bHET embryos. Together, these findings suggest that germline gata2b dosage modifies the developmental impact of asxl1 variants in HSPCs and lymphoid progenitors, a pattern reminiscent of early clonal selection in GATA2-deficient patients who acquire ASXL1 mutations. Ongoing work will define the mechanisms underlying this context-dependent genetic interaction to clarify its role in pre-malignant transformation.

Serine Avagyan, MD, PhD: No relevant conflicts of interest to declare.